Stock Price & Analysis

Based on the provided data and recent market activity, here's a concise analysis of INCY stock:

Market Performance INCY has experienced significant selling pressure today, dropping 7.86% during regular trading hours to close at $68.30, with further weakness in after-hours trading showing an additional decline of 3.37%.

Technical Analysis The stock is showing bearish signals with:

• RSI-14 at 34.10 indicating oversold conditions but not yet at extreme levels
• Current price ($68.30) has broken below the Fibonacci support level of $69.09
• Next major support level lies at $66.87

Recent Events Impact The sharp decline today was triggered by weaker-than-expected Q4 2024 earnings, with adjusted EPS of $1.43 falling short of the $1.49 consensus. This disappointing result has led to immediate selling pressure.

Forward Outlook Despite today's decline, there are several potential catalysts ahead:

• Four potential drug launches expected in 2025 that could generate ~$1 billion in incremental revenues by 2029
• Multiple pivotal trial results and proof-of-concept data readouts scheduled throughout 2025
• Phase 3 data for povorcitinib in hidradenitis suppurativa expected in H1 2025, targeting a $3 billion US market

Recommendation Given the technical breakdown and earnings miss, combined with near-term selling pressure, investors should wait for price stabilization before considering new positions. The next strong support level at $66.87 could provide a better entry point once selling pressure subsides.

Based on the provided data and recent market activity, here's the price prediction analysis for INCY stock:

Current Market Status and Price Movement

INCY stock is currently trading at $66.00, showing significant weakness with a -7.86% decline during regular trading hours and an additional -3.37% drop in post-market trading . The stock has experienced heavy selling pressure with above-average volume of 3.78 million shares.

Technical Analysis

• The stock is showing bearish momentum with RSI at 34.10, indicating oversold conditions
• Current price is trading below its 20-day moving average of $73.01, suggesting a negative short-term trend
• Fibonacci support levels indicate next key support at $69.09, with stronger support at $66.87

Fundamental Catalysts

• The company reported Q4 2024 earnings below consensus ($1.43 vs expected $1.50)
• Incyte has outlined 2025 as a "transformational year" with four potential drug launches that could contribute approximately $1 billion in incremental revenues by 2029
• Multiple catalysts expected including four pivotal trial results and seven proof-of-concept data readouts

Price Prediction for 2025 Based on the technical weakness and recent earnings miss, but considering the strong pipeline potential, INCY stock is expected to trade in the range of $85-90 by end of 2025, representing about 30% upside from current levels, driven primarily by successful execution of planned drug launches and positive clinical trial results.

The S1 support level for INCY Stock is $67.94 ,The R1 resistant level for INCY Stock is $76.11.

As of the end of day on 2025-02-11, the price of INCY Stock was $66.37.

The target price for INCY Stock according to analyst rating is 76.77, with the highest price target at 100.00 and the lowest at 52.00. Analysts have a Moderate Buy rating on INCY Stock overall.

The market cap of INCY is $12.8B.

Based on the provided data and recent market developments, INCY appears to be fairly valued with some concerns. The company's P/E ratio has increased significantly from 17.29x to 714.44x in Q3 2024, indicating potential overvaluation compared to historical levels. Net margin volatility is concerning, swinging from 19.25% to -42.6% and then to 9.36% across quarters. The current technical indicators show RSI at 34.10, suggesting oversold conditions but requiring caution.

Recent analyst consensus remains predominantly neutral, with 11 out of 15 analysts maintaining "Hold" ratings. The average price target of $73.27 suggests limited upside potential from current levels.

The company is positioning for a transformational 2025 with four potential drug launches expected to contribute approximately $1 billion in incremental revenues by 2029. However, this growth potential appears to be already priced into the current valuation.

The stock's current technical position below both its 20-day SMA ($73.01) and showing negative MACD histogram (-0.28) suggests near-term weakness in price momentum.

Incyte Corporation is a biopharmaceutical company, which is focused on the discovery, development, and commercialization of therapeutics. The Company also conducts clinical development and commercial operations from its European headquarters in Morges, Switzerland and its other offices across Europe, as well as its Japanese office in Tokyo and its Canadian headquarters in Montreal. It operates in two therapeutic areas, One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. Its other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise are comprised of four products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib), ICLUSIG (ponatinib), and ZYNYZ (retifanlimab-dlwr), as well as numerous clinical development programs.

Based on the provided data and recent market activity, here's the price prediction for INCY stock by 2030:

INCY stock is projected to reach $95-100 by 2030, driven by the company's transformational growth strategy including multiple drug launches and pipeline expansion. The company expects approximately $1 billion in incremental revenues by 2029 from four potential drug launches, suggesting sustained revenue growth trajectory towards 2030.

The current technical indicators showing RSI at 34.10 and recent price decline to $66 indicate the stock is currently oversold, providing potential upside from current levels over the long-term horizon.

INCY has a total of 2524 employees.